| Hematopoietic stem cell transplantation K Khaddour, CK Hana, P Mewawalla | 154 | 2019 |
| Does thrombocytopenia truly correlate with COVID-19 severity? C Hana, S Aboulenain, N Dewaswala, V Narendran Blood 136, 39-40, 2020 | 11 | 2020 |
| Hematopoietic Stem Cell Transplantation. 2021 Jul 25 K Khaddour, CK Hana, P Mewawalla StatPearls. Treasure Island (FL): StatPearls Publishing, 2022 | 8 | 2022 |
| Hypereosinophilic syndrome, multiorgan involvement and response to imatinib CK Hana, H Caldera Cureus 12 (6), 2020 | 4 | 2020 |
| Pancreatic adverse events in patients treated with immune checkpoint inhibitors C Hana, T Rehman, K Park, C Carracedo Uribe, PP Aung, B Hunis, ... JGH Open 7 (3), 204-207, 2023 | 3 | 2023 |
| Uterine sarcomas, insight into its risk factors: A systematic review. C Hana, GZ D'Amato Journal of Clinical Oncology 38 (15_suppl), e23540-e23540, 2020 | 3 | 2020 |
| Dose escalation of ripretinib can lead to response in advanced gastrointestinal stromal tumor patients refractory to the standard dose: A report of two cases PA Costa, CKA Hana, NC Balaji, AF Skryd, BN Valdes, RO Minjares, ... Gastrointestinal Stromal Tumor 4, 2021 | 2 | 2021 |
| Mutations highly specific for secondary AML are associated with poor outcomes in ELN favorable risk NPM1-mutated AML O Chan, N Al Ali, H Tashkandi, A Ellis, S Ball, J Grenet, C Hana, ... Blood Advances 8 (5), 1075-1083, 2024 | 1 | 2024 |
| The prognostic impact of FLT3 in NPM1-mutated AML: Co-occurrence of FLT3-ITD and FLT3-TKD confers poor outcomes O Chan, N Al Ali, S Ball, J Grenet, C Hana, YE Deutsch, H Tashkandi, ... Blood 140 (Supplement 1), 3435-3437, 2022 | 1 | 2022 |
| Secondary AML Mutations Confer Poor Prognosis in Patients with ELN Favorable Risk NPM1-Mutated AML O Chan, NA Ali, H Tashkandi, A Ellis, S Ball, J Grenet, C Hana, ... Blood 140 (Supplement 1), 3419-3421, 2022 | 1 | 2022 |
| Refining Blood Products Utilization: Every One (unit) Matters. Post-Intervention Study C Hana, K Deeb, K DeSuza, SG Smith, S Ivanov, L Lit Blood 136, 27-28, 2020 | 1 | 2020 |
| Therapeutic Targeting of Hypoxia-Inducible Factors in Cancer S Musleh Ud Din, SG Streit, BT Huynh, C Hana, AN Abraham, A Hussein International Journal of Molecular Sciences 25 (4), 2060, 2024 | | 2024 |
| Molecular Targeting of the Claudins Pathway. C Hana, NNT Dar, MG Venegas, M Vulfovich Preprints, 2024 | | 2024 |
| Claudins in Cancer: A Current and Future Therapeutic Target C Hana, NN Thaw Dar, M Galo Venegas, M Vulfovich International Journal of Molecular Sciences 25 (9), 4634, 2024 | | 2024 |
| Second-Line Chimeric Antigen Receptor T Cell Therapy (CAR-T) As Standard of Care for Relapsed-Refractory Large B-Cell Lymphoma (LBCL) S Dahiya, JY Spiegel, D Lee, T Mohammed, F Lutfi, A Goyal, C Hana, ... Blood 142, 4876, 2023 | | 2023 |
| The impact of hispanic ethnicity in presentation and outcomes of patients with synovial sarcoma. P Barreto Coelho, C Hana, N Yanchenko, S Bialick, A Rosenberg, A Dhir, ... Journal of clinical oncology 41 (16_suppl), e18682-e18682, 2023 | | 2023 |
| A retrospective analysis of gender disparities in clinical outcomes of patients diagnosed with non-uterine leiomyosarcoma. C Hana, O Nano, S Samuels, AM Hussein, A Wadhawan Journal of Clinical Oncology 40 (16_suppl), e23547-e23547, 2022 | | 2022 |
| Differential outcome of females with uterine versus extra-uterine leiomyosarcomas, a retrospective analysis. C Hana, O Akinbobuyi, A Wadhawan, S Samuels, AM Hussein Journal of Clinical Oncology 40 (16_suppl), e23557-e23557, 2022 | | 2022 |
| Erythrocytosis As A Paraneoplastic Syndrome in A Case of Angiosarcoma C Hana, G Hanna, A Hussein Journal of Cancer Science and Clinical Therapeutics 6 (2), 239-243, 2022 | | 2022 |
| Differential risk factors between uterine sarcomas and malignant mixed Müllerian tumors. C Hana, PA Costa, GZ D'Amato, JC Trent Journal of Clinical Oncology 39 (15_suppl), e23551-e23551, 2021 | | 2021 |
